Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 11 of 11

List	Outcome	Time frame	Description
Primary	Accuracy of Device-measured vancomycin ISF concentration vs. paired serum concentration	Up to 5 Days	Comparison of vancomycin concentration-time profiles and pharmacokinetic parameters (Cmax, Tmax, Cmin, AUC0-24) derived from interstitial fluid (Sensor Device) against paired serum vancomycin immunoassay results.
Primary	Accuracy of Device-measured biomarker (creatinine, C-reactive protein, lactate) ISF concentration vs. paired serum concentration	Up to 5 days	Determination of accuracy between Device-reported biomarker values and paired serum immunoassay results.
Primary	Relationship between ISF analyte concentrations and clinical outcomes	Through 30 days after study completion	Descriptive summary of association between ISF concentration profiles (vancomycin, creatinine, C-reactive protein, lactate) and 30-day clinical outcomes (discharge/readmission, morbidity, mortality, treatment-emergent adverse events).
Primary	General performance characterisation of the Device	Up to 5 days	Paired precision between simultaneously worn devices; device accuracy throughout wear duration; electrochemical sensor quality metrics.
Secondary	Device performance across patient subgroups	Up to 5 days	Exploratory analysis of Peak Plasma Concentration (Cmax) by demographic and clinical subgroup (age, sex, ethnicity, BMI, medical conditions/pathologies).
Secondary	Device performance across patient subgroups	Up to 5 days	Exploratory analysis of Time to Peak Concentration (Tmax) by demographic and clinical subgroup (age, sex, ethnicity, BMI, medical conditions/pathologies).
Secondary	Device performance across patient subgroups	Up to 5 days	Exploratory analysis of Minimum Blood Plasma Concentration (Cmin) by demographic and clinical subgroup (age, sex, ethnicity, BMI, medical conditions/pathologies).
Secondary	Device performance across patient subgroups	Up to 5 days	Exploratory analysis of Area Under the Curve (AUC0-24) by demographic and clinical subgroup (age, sex, ethnicity, BMI, medical conditions/pathologies).
Secondary	Stability and precision of the Device over time, compared to standard laboratory assays	Up to 5 days	Assessment of device reporting accuracy compared to reported values from standard laboratory assays across wear duration, including after 48-hour device replacement.
Secondary	Incidence of Adverse Events	From first device application to 30 days post study completion	Frequency, severity and seriousness of adverse reactions associated with the Device; descriptive summary of application-site photographs.
Secondary	Accuracy of Device-reported trend toward Acute Kidney Injury (AKI)	Up to 5 days	Determination of accuracy between Device-reported creatinine trend and serum creatinine; AKI assessed per KDIGO Clinical Practice Guideline for Acute Kidney Injury (2012).

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT07893223/registered

API reference For AI assistants